The emergence of drug-resistant tuberculosis (TB) is a challenge to TB control in Europe. We evaluated secondline drug susceptibility testing in Mycobacterium tuberculosis isolates from patients with multidrugresistant, pre-extensively drug-resistant (pre-XDR-TB) and XDR-TB at 23 TBNET sites in 16 European countries. Over 30% of bacilli from patients with pre-XDR-TB showed resistance to any fluoroquinolone and almost 70% to any second-line injectable drug. Respectively .90% and .80% of the XDR-TB strains tested showed phenotypic resistance to pyrazinamide and ethambutol. Resistance to prothionamide/ethionamide was high in bacilli from pre-XDR-TB patients (43%) and XDR-TB patients (49%). K E Y W O R D S : Europe; drug resistance; MDR-TB; TB; extensively drug-resistant tuberculosis; Tuberculosis Network European Trials THE EMERGENCE OF DRUG-RESISTANT strains of Mycobacterium tuberculosis is a challenge to global tuberculosis (TB) control. 1 Multidrug-resistant TB (MDR-TB) is defined as in vitro resistance to at least rifampicin (RMP) and isoniazid (INH). Preextensively drug-resistant TB (pre-XDR-TB) is defined as additional resistance to either a World Health Organization (WHO) Group 2 injectable drug (second-line injectables [SLIs] such as amikacin, capreomycin, kanamycin) or a WHO Group 3 fluoroquinolone (FQ). 2 In XDR-TB, additional resistance to at least one drug from both WHO Groups 2 and 3 is present. 2 Treatment outcomes are directly related to the level of drug resistance in M. tuberculosis. In a meta-analysis based on 6724 cases, treatment success was respectively 64%, 56%, 48% and 40% in MDR-TB, pre-XDR-TB (SLI resistance), pre-XDR-TB (FQ resistance) and XDR-TB patients. 3 Recent surveillance data from the European Centre of Disease Prevention and Control (ECDC, Stockholm, Sweden) showed treatment success in only 31% of MDR-TB and 19% of XDR-TB patients in Europe. 4 Second-line anti-tuberculosis drug susceptibility testing (DST) is performed in only 21% of bacilli from notified MDR-TB patients in the European Region. 4 We evaluated data from a prospective multinational observational cohort of MDR-/XDR-TB patients in Europe to identify patterns of second-line drug resistance in M. tuberculosis and risk factors for pre-XDR and XDR-TB. As part of the European Union (EU) funded TBPANNET, the present study was conducted between January 2010 and February 2014 at 23 Tuberculosis Network European Trials (TBNET; www.tb-net.org) sites specialising in the care of MDR-/XDR-TB patients in 16 European countries: 2 high TB incidence (.100 per 100 000 population), 4 intermediate incidence (20-100/ 100 000) and 10 low incidence (,20/100 000). 5 
METHODS
Patients who provided informed consent and were started on treatment for a new episode of cultureconfirmed MDR-TB (resistance to at least RMP and INH) were eligible for enrolment, as described elsewhere. 3 All consecutive MDR-TB patients who gave consent at each site during the study period were included in the cohort. Ethics approval was obtained from the University of Lübeck, Lübeck, Germany, and subsequently at other participating sites. An electronic case record form (www.openclinica.com) was used for data collection.
Patients were classified as having MDR-TB, pre-XDR-TB or XDR-TB based on DST results for the culture-positive sputum specimen obtained closest to the start of appropriate treatment for this resistance pattern. All laboratories at the study sites were qualitycontrolled by the WHO Supranational Reference Laboratory Network. Phenotypic testing was performed at all sites using liquid culture, with the exception of Romania. The frequency of DST and the proportion of strains classified as resistant are reported for individual drugs and specific groups of drugs.
Ordinal logistic regression was performed to assess variables associated with increased drug resistance, in which the outcome variable was ordered as MDR-, pre-XDR-and XDR-TB. All included variables were dichotomised. To align with earlier analyses in the current cohort and other studies, age was dichotomised at 45 years. Variables were included in a multivariable model if P , 0.10 in the univariable model. Odds ratios (ORs) with their associated 95% confidence intervals (CIs) were calculated. The level of statistical significance was set at 5%.
RESULTS
The cohort included 380 patients with at least RMPand INH-resistant M. tuberculosis. Bacillary strains from 356 (93.7%) patients were tested for at least one SLI, and 352 (92.6%) for an FQ. A total of 33 (8.7%) patients were classified as XDR-TB based on the DST results, and 89 (23.4%) as pre-XDR-TB. Table 1 shows low DST capacity for later-generation FQs (levofloxacin and moxifloxacin) and linezolid at the participating centres in Europe. Bacilli from patients with pre-XDR-TB showed .30% resistance to any FQ and almost 70% to any SLI. Respectively .90% and .80% of the tested XDR-TB M. tuberculosis strains showed phenotypic resistance to pyrazinamide (PZA) and ethambutol. Additional resistance to prothionamide/ethionamide was high in bacilli from both pre-XDR-(43%) and XDR-TB patients (49%). DST against Group 5 drugs was rarely performed.
Previous anti-tuberculosis treatment and age ,45 years were independent risk factors for MDR-TB in this cohort. 5, 6 Table 2 shows the results of the multinomial logistic regression analysis. None of the risk factors were seen to have a predictive value with regard to an increased level of drug resistance.
DISCUSSION
In this European cohort of patients infected with M. tuberculosis strains and resistance to at least RMP and INH, almost one quarter of infecting strains showed additional resistance to either an SLI or an FQ at the start of treatment (pre-XDR-TB), while 8.7% of the MDR-TB strains fulfilled our definition for XDR-TB. PZA resistance testing was infrequently performed in high proportions of resistance in M. tuberculosis strains (44.9% for MDR-, 78.5% for pre-XDR-and 94.4% for XDR-TB). These findings challenge the current WHO recommendation, issued in 2011, of treating all MDR-TB patients with PZA, and limit the possible use of this drug in new regimens currently under development. 7, 8 The importance of drug resistance in addition to RMP and INH resistance in relation to treatment success was recently highlighted in an analysis of 9153 MDR-TB patients. The study demonstrated the association of in vitro susceptibility to first-and second-line drugs with higher odds of treatment success. 9 Additional in vitro resistance, as observed in this European cohort, is thus likely to increase the frequency of treatment failure. This finding is complicated by the fact that the risk of acquired drug resistance during anti-tuberculosis treatment increases substantially with increasing resistance to other drugs in the regimen. 10 Results from this observational cohort study suggest that wider use of DST might reveal high levels of second-line anti-tuberculosis drug resistance in Europe, including a higher frequency of XDR-TB. The combination of the low frequency of DST against second-line drugs, and the finding of high resistance levels to those drugs when tested, might explain the recently reported low treatment success rate for MDR-TB in Europe. 4 In agreement with the results from the Preserving Effective TB Treatment Study (PETTS), we did not find any association between selected risk factors and increasing levels of drug resistance. 10 Individual risk factors present for MDR-TB could therefore well be indicative of underlying pre-XDR-or XDR-TB, thus necessitating DST for second-line drugs. Our study has several limitations. Data were derived from an international multicentre observational cohort study and not from routine drug resistance surveillance. Although hospitals specialising in the care of MDR-/XDR-TB patients from 14 of 28 EU and 2 non-EU countries participated in the study, the data may not be generalisable to all of Europe. Selection bias due to the inclusion of only MDR-TB cases who were severely ill is thought to be limited, given the consecutive sampling approach and the fact that MDR-/XDR-TB was treated in only a few specialist centres in each country. For greater representativeness of the data, we also performed weighted analyses stratified by incidence based on the sampling fraction and the expected number of notified MDR-TB patients in the countries from which patients were recruited. These results suggest that, at the very least, frequencies of resistance against second-line drugs might even have been underestimated in our cohort (data not shown).
In conclusion, we identified a low frequency of DST coverage for later-generation FQ and WHO Class 5 anti-tuberculosis drugs, and a high frequency of M. tuberculosis strains resistant to second-line anti-tuberculosis drugs in addition to RMP and INH. Our findings contribute to a better understanding of the poor treatment outcomes in MDR-TB patients in Europe, 4 and argue against the use of standardised drug regimens for MDR-TB treatment in this region. Our results indicate the urgent need to scale up molecular (genotypic) and phenotypic second-line DST in Europe to obtain much needed results before treatment start and to facilitate the use of appropriate and effective regimens for patients with drug-resistant TB. La pharmacorésistance au prothionamide/éthionamide aétéélevée pour les bacilles de patients atteints de TB pré-XDR (43%) et TB-XDR (49%).
R E S U M E N
La aparición de tuberculosis (TB) farmacorresistente representa un peligro en el control de la TB en Europa. En el presente estudio se evaluaron dos pruebas de sensibilidad de Mycobacterium tuberculosis a los medicamentos de segunda línea, en pacientes con TB multidrogorresistente (TB-MDR), pre-extremadamente drogorresistente (TB pre-XDR) y TB-XDR provenientes de 23 centros del grupo TBNET en 16 países europeos. Má s del 30% de los bacilos provenientes de los pacientes con TB pre-XDR exhibió resistencia a todas las fluoroquinolonas y cerca del 70% fue resistente a todos los medicamentos inyectables de segunda línea. De las cepas causantes de TB-XDR estudiadas, má s del 90% presentó resistencia a pirazinamida y má s del 80% a etambutol. La farmacorresistencia a protionamida y etionamida fue alta en los bacilos de pacientes con TB pre-XDR (43%) y TB-XDR (49%).
